SEED Entered into Strategic Research Collaboration with Eisai and Closed First Round of Series A Financing in August 2024.
SEED Achieved 3rd Milestone with Lilly R&D Collaboration in March 2024.
SEED Discloses Novel Molecular Glue IND Candidate at “TPD Think Tank” Symposium.
SEED Therapeutics’ Mission
To break through the scientific barriers to discovering Molecular Glues for effective therapy and cures for the world’s most debilitating diseases and disorders.
Collaborating with an unparalleled team of world-leading experts in the Ubiquitin Proteasome System and the field of Targeted Protein Degradation. SEED Therapeutics is advancing its groundbreaking Molecular Glues discovery platform for the treatment of multiple indications, including cancer, neurodegradation, and infectious diseases.
DRUG DISCOVERY
SEED Therapeutics: A focus on Molecular Glues
SEED Therapeutics is a global research company uniquely focused on harnessing and engineering molecules that use Molecular Glues to attack protein targets previously believed to be ”undruggable.”
PIPELINE
THE TEAM
Click below to learn more about SEED Therapeutics’ leadership
NEWSROOM
Seed Therapeutics Launches Protein Degradation Research Platform and Appoints Edward Dongheng Liu as Chief Financial Officer
info@seedtherapeutics.com info@seedtherapeutics.com PRESS RELEASESSeed Therapeutics Launches Protein Degradation Research Platform and Appoints Edward Dongheng Liu as Chief Financial Officer “Molecular Glue” Protein Degradation Serves as Alternative Approach for...
Events
“Targeted Protein Degradation Think Tank” Symposium
PARTNERS
CAREERS
Make a difference in improving human health
CONTACT US
Investor Contact: IR@seedtherapeutics.com
Media Contact: PR@seedtherapeutics.com
General Inquires: info@seedtherapeutics.com